ライフサイエンスコーパス: zoster

1 he treatment of VZV infections (i.e., herpes zoster).

2 2-dose regimen, and probability of recurrent zoster.

3 development of treatments for painful herpes zoster.

4 to establish latency and reactivate, causing zoster.

5 hly contagious agent of varicella and herpes zoster.

6 onia, and an increase observed for varicella zoster.

7 the causative agent of varicella and herpes zoster.

8 can reactivate later in life to cause herpes zoster.

9 been associated with severe varicella and/or zoster.

10 pment of novel treatments for painful herpes zoster.

11 ical malignancies is at high risk for herpes zoster.

12 nsient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (4.8%) i

13 E Varicella-zoster virus (VZV) causes herpes zoster, a major health issue in the aging and immunocomp

14 95% confidence interval 1.00-1.08) or herpes zoster (adjusted HR 1.03; 95% confidence interval 1.00-1

15 consistent evidence of an increased risk of zoster after partner death.

16 ect influences on the epidemiology of herpes zoster among children.

17 ent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic neuralgia

18 ne effectiveness of about 62% against herpes zoster and 70-88% against postherpetic neuralgia.

19 malignancy have an increased risk of herpes zoster and herpes zoster-related complications.

20 e, reactivating in one-third to cause herpes zoster and occasionally chronic pain.

21 ate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations.

22 vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this population.

23 ns with patients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring between Oct

24 ns administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated these

25 nuated vaccine against chickenpox and herpes zoster and providing a new target for intervention of ne

26 icella zoster virus reactivation (ophthalmic zoster) and incident dementia (HR 2.97; 95%CI, 1.89 to 4

27 ) for oral candidiasis, tuberculosis, herpes zoster, and bacterial pneumonia.

28 and viral (due to herpes simplex, varicella zoster, and enteroviruses) meningitis/encephalitis, neur

29 her infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus, and herpes

30 To examine whether herpes zoster antigen (also called varicella-zoster virus antig

31 Herpes zoster antigen was detected in 3 of 25 temporal arteries

32 patients, false-positive staining for herpes zoster antigen was detected in the presence of calcifica

33 False-positive staining for herpes zoster antigen was detected on several temporal artery b

34 Among the GCA-negative group, herpes zoster antigen was not detected in any biopsy.

35 3 patients had positive staining for herpes zoster antigen.

36 While most cases of varicella or zoster are self-limited, patients with certain immune de

37 wed the literature for cases of varicella or zoster associated with primary and acquired immunodefici

38 eporting incidences of chickenpox and herpes zoster before and after implementation of chickenpox vac

39 is an important human pathogen, with herpes zoster being a major health issue in the aging and immun

40 ncidences of cytomegalovirus disease, herpes zoster, BK virus, and nephropathy, which led to the disc

41 ry, and the annual rates of change in herpes zoster by age category, in an interrupted time series re

42 monly thought to increase the risk of herpes zoster by causing immunosuppression.

43 vealed a net increase of hospitalized herpes zoster cases in individuals aged 10-49 years after imple

44 No herpes zoster cases or major adverse cardiac events including t

45 Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax)

46 (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus and Toxoplas

47 We included patients with a zoster diagnosis from the primary care or hospital-based

48 lgia is the most important symptom of herpes zoster disease and it is very difficult to treat.

49 lgia is the most important symptom of herpes zoster disease, which is caused by Varicella zoster Neve

50 low-up, 20286 new cancer diagnoses and 16350 zoster events occurred.

51 lphaherpesvirus causing varicella and herpes zoster, expresses 24 virally encoded sncRNA (VZVsncRNA)

52 e three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0.65 [95% 0.60-

53 Children with varicella or zoster from 5 Paediatric Active Enhanced Disease Surveil

54 of millions of seniors are at risk of herpes zoster (HZ) and its complications.

55 The primary reported risk factors for herpes zoster (HZ) are increasing age and immunodeficiency yet

56 la vaccination on the epidemiology of herpes zoster (HZ) critically depends on the mechanism of immun

57 The incidence of herpes zoster (HZ) has been increasing in recent decades.

58 gency department (ED) utilization for herpes zoster (HZ) has not been examined to date.

59 emporal increases in the incidence of herpes zoster (HZ) have been reported but studies have examined

60 ) due to concerns this could increase herpes zoster (HZ) incidence.

61 The primary reported risk factors for herpes zoster (HZ) include increasing age and immunodeficiency,

62 The incidence and severity of herpes zoster (HZ) increases with age.

63 Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccin

64 mised adults are at increased risk of herpes zoster (HZ) infection and related complications.

65 ised adults are at .increased risk of herpes zoster (HZ) infection and related complications.

66 Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time.

67 healthy population, the protection of herpes zoster (HZ) vaccine in end-stage renal disease (ESRD) pa

68 erstanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine

69 adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated H

70 Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated immunocomp

71 Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated, immunocom

72 hich later was clinically found to be herpes zoster (HZ).

73 can reactivate later in life, causing herpes zoster (HZ).

74 Although the annual incidence of herpes zoster in adults has continued to increase, the rates of

75 ricella-zoster virus vaccine prevents herpes zoster in adults older than 50 years.

76 ubstantial population-level impact on herpes zoster in nonvaccinated age groups.

77 zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem

78 10 to 49 days posttreatment, with recurrent zoster in one treated monkey.

79 serious infections, and four cases of herpes zoster in patients who received tofacitinib during the t

80 Estimated vaccine efficacy against herpes zoster in patients with solid tumour malignancies was 63

81 n impact of chickenpox vaccination on herpes zoster incidence and time trend, focusing on population-

82 The increase in age-adjusted herpes zoster incidence before implementation of chickenpox vac

83 In the antiretroviral therapy era, herpes zoster incidence continued to decline in people living w

84 The primary efficacy endpoint was herpes zoster incidence in patients with solid tumour malignanc

85 Herpes zoster incidence rates have continued to increase in age

86 Historic herpes zoster incidence trends in US adults have been hard to i

87 ffectiveness, duration of protection, herpes zoster incidence, and probability of postherpetic neural

88 the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0.67 [0.61-0.74]) and 38% f

89 s during 1996-2006 and 2007-2016, the herpes zoster incidences increased at annual rates of 1-5%.

90 In 1991-1995, the herpes zoster incidences increased at annual rates of 4-6% in a

91 The annual incidences of herpes zoster increased throughout the period of 1991-2012 in a

92 wed a significant increase in risk of herpes zoster infection among patients who received JAK inhibit

93 alysis, we found an increased risk of herpes zoster infection among patients with immune-mediated dis

94 nd the rates of overall infection and herpes zoster infection were higher with tofacitinib than with

95 ncidence rates of serious infections, herpes zoster infection, malignancy, and major cardiovascular e

96 ncidence rates of serious infections, herpes zoster infection, non-melanoma skin cancer, other malign

97 e were four serious infections, three herpes zoster infections, one myocardial infarction, and one is

98 % CI, 3.5-3.7]) and highest for disseminated zoster (IRR, 32.8 [95% CI, 27.8-38.6]).

99 95%CI 3.5-3.7) and highest for disseminated zoster (IRR=32.8, 95%CI 27.8-38.6).

100 Herpes zoster is linked to amyloid-associated diseases, includi

101 No serious infections, herpes zoster, malignancy, venous thromboembolic events, or dea

102 chickenpox vaccination, incidences of herpes zoster may rise.

103 immunocompromised) had varicella (n = 2) or zoster (n = 2) due to the Oka/vaccine strain.

104 ildren with confirmed varicella (n = 238) or zoster (n = 89) were enrolled.

105 zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological mechanisms i

106 erson-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, compared

107 ention-to-treat population, confirmed herpes zoster occurred in 22 of 1328 (6.7 per 1000 person-years

108 of ophthalmoplegia in the setting of herpes zoster ophthalmicus (HZO) is controversial.

109 Recurrences of zoster ophthalmicus are uncommon because the reactivatio

110 cord can reliably be used to identify herpes zoster ophthalmicus cases.

111 oteworthy because the patient had had herpes zoster ophthalmicus diagnosed 3 weeks before the onset o

112 Herpes zoster ophthalmicus occurs primarily in elderly or immun

113 We report a case of herpes zoster ophthalmicus-related ophthalmoplegia (HZORO) in w

114 ic with a history of multiple recurrences of zoster ophthalmicus.

115 novel TLR3 variant associated with recurrent zoster ophthalmicus.

116 settings were analyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN).

117 ransient increase in the incidence of herpes zoster, peaking in adults 15-35 years after the start of

118 tcome measures were the incidences of herpes zoster per 100 000 person-years, by calendar year and ag

119 ypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune dise

120 Information on the risks of herpes zoster (zoster) preceding a cancer diagnosis and the role of can

121 The hypothesized increase in herpes zoster predicted from modelling of the exogenous boostin

122 ld-type varicella delays the onset of herpes zoster, predicts a transient increase in the incidence o

123 otherapy, but was not efficacious for herpes zoster prevention in patients with haematological malign

124 as well tolerated and efficacious for herpes zoster prevention in patients with solid tumour malignan

125 icella zoster virus (VZV) vaccine for herpes zoster prevention in patients with solid tumour or haema

126 V reactivation, with virus antigens found in zoster rash and SVV DNA and antigens found in lungs, lym

127 Zoster rash developed after 7 days in the monkey with th

128 n increased risk of herpes zoster and herpes zoster-related complications.

129 Compared to those without cancer, zoster risk among participants with solid cancers receiv

130 For hematological cancer, increases in zoster risk are apparent in the 2 years preceding diagno

131 Compared to those without cancer, zoster risk was also elevated prior to a hematological c

132 ion between cancer diagnosis, treatment, and zoster risk was analyzed using time-varying proportional

133 Herpes zoster (shingles) causes significant morbidity in immune

134 ZV causes varicella (chicken pox) and herpes zoster (shingles), while HCMV causes serious disease in

135 ogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministered with

136 nd solid cancer had higher relative risks of zoster than those without cancer (adjusted hazard ratio

137 We evaluated pediatric herpes zoster trends using administrative databases.

138 tion between partner bereavement and risk of zoster using electronic healthcare data covering the ent

139 assess the safety of live attenuated herpes zoster vaccination during 2011-2017 in US adults aged >=

140 INTERPRETATION: The herpes zoster vaccination programme in England has had a popula

141 In 2013, a herpes zoster vaccination programme was introduced in England f

142 We identified individual data on herpes zoster vaccinations administered and consultations for h

143 Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questio

144 ity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients.

145 The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacio

146 recommendations for use of a new recombinant zoster vaccine (RZV).

147 The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in o

148 Live attenuated zoster vaccine (Zostavax) was used to test the hypothesi

149 Immunogenicity and safety of inactivated zoster vaccine (ZVIN) were evaluated in adults with auto

150 cy and immunogenicity of the live attenuated zoster vaccine (ZVL) have a very-well-described negative

151 The live attenuated zoster vaccine (ZVL) provides the best example of a grad

152 d 286 participants to adjuvanted recombinant zoster vaccine and 283 to placebo.

153 tradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence

154 gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses.

155 Eligible patients received live zoster vaccine at investigators' discretion.

156 mmune response to the adjuvanted recombinant zoster vaccine at month 2 in all participants, excluding

157 reactogenicity of the adjuvanted recombinant zoster vaccine compared with placebo from the first vacc

158 ermine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity comp

159 The live attenuated zoster vaccine generates immune responses similar to HZ.

160 Each partial dose of zoster vaccine given intradermaly had a gpELISA GMFR com

161 received the approved full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intra

162 gpELISA GMFR comparable to that of full dose zoster vaccine given subcutaneously.

163 We compared the immune responses to zoster vaccine in young and older to adults to increase

164 Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time.

165 ompetent adults >=50 years unvaccinated with zoster vaccine live who had incident HZ in 2011-2015; (2

166 ent adults aged >=50 years unvaccinated with zoster vaccine live who had incident HZ in 2011-2015; (2

167 eive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or aft

168 Intradermal zoster vaccine showed a greater increase in varicella-zo

169 s zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years.

170 cine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose intradermal

171 ed: 52 to receive the full dose subcutaneous zoster vaccine, 34 to receive the 1/3 dose subcutaneous

172 ine, 34 to receive the 1/3 dose subcutaneous zoster vaccine, 34 to receive the full dose intradermal

173 ine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose intradermal z

174 ine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 dose intrader

175 l vaccine response to adjuvanted recombinant zoster vaccine, compared with one (0.8%, 0.0-4.2) of 130

176 The adjuvanted recombinant zoster vaccine, which is currently licensed in certain c

177 mmunization of a 78-year-old woman with live zoster vaccine.

178 and 34 to receive the 1/27 dose intradermal zoster vaccine.

179 to increase since introduction of the herpes zoster vaccines.

180 as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thygeson's su

181 erpes simplex virus (8.8%), 5 with varicella-zoster virus (4.9%), 27 with cytomegalovirus (26.5%), an

182 s (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), histoplasmo

183 The herpesviruses varicella-zoster virus (VZV) and human cytomegalovirus (HCMV) are

184 mpex virus 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV) and human herpesvirus 8 (HHV-8) were

185 on of herpesviruses, most commonly varicella-zoster virus (VZV) and pseudorabies virus (PRV), may cau

186 Varicella zoster virus (VZV) antibody titers (measured by a VZV gl

187 Infections with varicella-zoster virus (VZV) are associated with a range of clinic

188 types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain reaction i

189 ectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shingles.

190 from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shingles.

191 eatment of VZV diseases.IMPORTANCE Varicella-zoster virus (VZV) causes herpes zoster, a major health

192 Varicella-zoster virus (VZV) characteristically forms multinucleat

193 We studied a patient with varicella-zoster virus (VZV) CNS vasculopathy and as part of the e

194 In this report, we investigated varicella-zoster virus (VZV) egress in a cell line from a child wi

195 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong latent infecti

196 Varicella-zoster virus (VZV) establishes lifelong neuronal latency

197 ilar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measured by res

198 t for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of people world

199 echanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to study due to

200 e bone marrow.IMPORTANCE Childhood varicella-zoster virus (VZV) immunization induces immune memory re

201 for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of suspected

202 ty to detect antibody responses to varicella-zoster virus (VZV) in vaccinated individuals, who produc

203 with concurrent primary wild-type varicella-zoster virus (VZV) infection, in whom chickenpox rash de

204 Varicella-zoster virus (VZV) is a common pathogen that causes chic

205 Varicella-zoster virus (VZV) is a highly contagious agent of varic

206 Varicella-zoster virus (VZV) is a medically important human herpes

207 Varicella zoster virus (VZV) is a skin-tropic virus that infects e

208 Varicella-zoster virus (VZV) is a ubiquitous pathogen that causes

209 Varicella-zoster virus (VZV) is an alphaherpesvirus that lacks the

210 mediate early 62 (IE62) protein of varicella-zoster virus (VZV) is delivered to newly infected cell n

211 Varicella-zoster virus (VZV) is highly cell associated when grown

212 Varicella-zoster virus (VZV) is one of the most common agents caus

213 atients with giant cell arteritis, varicella zoster virus (VZV) is seen in perineurial cells that sur

214 Varicella zoster virus (VZV) is the causative agent of chickenpox

215 Varicella Zoster Virus (VZV) is the causative agent of varicella a

216 Varicella-zoster virus (VZV) is under consideration as a promising

217 tes that reexposure to circulating varicella zoster virus (VZV) over the life span inhibits reactivat

218 ium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and sensory ganglia

219 The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly manifested a

220 Varicella zoster virus (VZV) typically causes chickenpox upon prim

221 Varicella-zoster virus (VZV) vaccine appears to be safe and immuno

222 icacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster prevention

223 Although a varicella-zoster virus (VZV) vaccine has been used for many years,

224 unization with the live-attenuated varicella-zoster virus (VZV) vaccine induces protective immune res

225 immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

226 Varicella-zoster virus (VZV) vasculopathy produces stroke, giant c

227 matous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

228 MV), Epstein-Barr virus (EBV), and varicella zoster virus (VZV) was determined in crewmembers and gro

229 IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline and after v

230 ive lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).

231 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesvirus, resu

232 virus, herpes simplex virus (HSV), varicella zoster virus (VZV), and rubella.

233 us (SVV), the counterpart of human varicella-zoster virus (VZV), developed primary infection with vir

234 dically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virion envelope

235 atitis A (HAV), hepatitis B (HBV), varicella zoster virus (VZV), measles, and mumps.

236 od disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

237 icity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereafter, "varic

238 Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyloid.

239 To measure varicella-zoster virus (VZV)-specific immune responses using glyco

240 flow cytometry, we determined that varicella-zoster virus (VZV)-specific peak T helper 1 (VZV-Th1) re

241 individuals after reactivation of varicella zoster virus (VZV).

242 s herpes simplex viruses (HSV) and varicella zoster virus (VZV).

243 hat can occur with reactivation of varicella-zoster virus (VZV).

244 gainst hepatitis B virus (HBV) and varicella-zoster virus (VZV).

245 ge, which leads to reactivation of varicella zoster virus (VZV).

246 nd the sequence-divergent pathogen varicella zoster virus (VZV).

247 Our work has shown that varicella-zoster virus (VZV; also called human herpesvirus 3 [HHV3

248 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesvirus 3 [HH

249 activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspended, with

250 cytomegalovirus (HCMV) 11% in GCF; varicella zoster virus 6% in saliva and 3% in GCF; of human herpes

251 irus [CMV], herpes simplex I/II or varicella zoster virus [HSV/VZV], blood stream infection [BSI], in

252 athogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

253 HSV-1], HSV-2, JC virus [JCV], and varicella-zoster virus [VZV]).

254 sitive for herpes simplex virus or varicella zoster virus and evaluated between January 2002 and June

255 uman-restricted viruses.IMPORTANCE Varicella-zoster virus and human cytomegalovirus infect a majority

256 ior uveitis in his left eye due to varicella-zoster virus and Toxoplasma gondii coinfection documente

257 sociated with uveitis secondary to varicella-zoster virus and Toxoplasma gondii coinfection in a male

258 herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in temporal artery

259 ting, through which reexposures to varicella-zoster virus are thought to reduce the individual risk o

260 ibodies against a major antigen of varicella-zoster virus called gE.

261 Herpes simplex viruses 1 and 2 and varicella-zoster virus cause significant morbidity and mortality.

262 We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults

263 Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

264 ypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role of TLR3 g

265 Varicella zoster virus encephalitis was infrequent following high

266 mized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant System) and

267 ccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous

268 ators restores immune responses to varicella-zoster virus in vaccinees.

269 infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, with herpes

270 Available varicella-zoster virus models can be classified in 3 main families

271 ion in human herpesviruses such as varicella-zoster virus or herpes simplex viruses.

272 d children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfection.

273 lity showed an association between varicella zoster virus reactivation (ophthalmic zoster) and incide

274 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults ol

275 for herpes simplex virus (HSV) and varicella zoster virus was done in 237 (69%) and 82 (24%) patients

276 , EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old children.

277 s, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex virus 2,

278 herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryptococcus g

279 at childhood infections, including varicella zoster virus, are associated with an increased risk of a

280 owing to either herpes simplex or varicella zoster virus, by using the Standardization of Uveitis No

281 other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navigate in ne

282 together with baseline immunity to varicella-zoster virus, explains the effect of age on the immunoge

283 vels were highest in patients with varicella-zoster virus, hepatitis, or malaria (median, 1,935, 1,92

284 members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epstein-Barr vi

285 ovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyssavirus, he

286 ponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and Herpesviruse

287 associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uveitis.

288 t elicited an exceptionally strong varicella zoster virus-specific B-cell and CD8 T-cell response.

289 e from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA) measured a

290 o activated by the closely related varicella zoster virus.

291 ns or recombination with wild-type Varicella zoster virus.

292 lex virus and 8 patients (38%) had varicella zoster virus.

293 herpes simplex viruses 1 and 2 and varicella-zoster virus.

294 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) may cause severe infections in ser

295 ty to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common condition of empl

296 nd estimated vaccine efficacy against herpes zoster was 16.8% (95% CI -17.8 to 41.3).

297 Herpes zoster was reported by one (<1%) patient on continued me

298 association between partner bereavement and zoster were 1.05 (99% confidence interval, 1.03-1.07) in

299 mes of myocardial infarction (MI) and herpes zoster were also studied.

300 in source isolation, developed disseminated zoster with rash present for 1 day before being transfer

301 Information on the risks of herpes zoster (zoster) preceding a cancer diagnosis and the rol